Best Andreas Ryll Podcasts (2025)

1
2025 US Policy Highlights - Most Favored Nation (MFN) 51:18

3h ago51:18

51:18

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on Most Favored Nation (MFN) drug pricing and its knock-on effects for jobs, state budgets, and the generic supply chain. Over the past year, proposals to link U.S. prices to those in other countries have collided with inf…

1
2025 U.S. Policy Highlights - Inflation Reduction Act (IRA) Part 1 37:38

6d ago37:38

37:38

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduction Act (IRA) and its ripple effects across drug development, Medicare, and patient access. Over the past year, the biopharma industry and the broader healthcare system have undergone a period of rap…

1
Steffen Thirstrup & Richard Bergstrom: Evidence, Access, and Competitiveness in Europe 34:38

15d ago34:38

34:38

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts in European regulation and evidence of new medicines: Steffen Thirstrup: Chief Medical Officer at European Medicines Agency. Richard Bergstrom: Head of Policy at IQVIA. They compare regulatory benefit-risk decisions with HTA’s comparative effectiveness and ec…

1
Malina Müller: Rethinking Accelerated Approvals in Europe 27:30

30d ago27:30

27:30

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Dr. Malina Müller, Head of Health Economics at WifOR Institute, to explore the heated debate around accelerated and conditional approvals in Europe, how demographic and budget pressures shape HTA decisions, the tradeoffs between surrogate endpoints and overall survival, …

1
VT's Grumpies Talk MFN 29:32

2M ago29:32

29:32

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with two Vital Transformation colleagues to explore key trends in drug pricing and macroeconomic policy: Joe Hammang: US Business Director at Vital Transformation. Harry Bowen: Consulting Economist at Vital Transformation. They unpack the Trump administration’s “Most Favor…

1
Bettina Ryll, Kjetil Taskén & Anni Lepland: PRIME-ROSE & EU Joint Action 22:29

3M ago22:29

22:29

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three leaders advancing precision cancer medicine implementation in Europe: Bettina Ryll: Stockholm School of Economics, Institute for Research; Founder, Melanoma Patient Network Europe. Kjetil Taskén: Head of the Institute for Cancer Research, Oslo University Hospital; …

1
John Murphy: Generics, Biosimilars, and U.S. Policy 44:43

3M ago44:43

44:43

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with John Murphy, President and CEO of the Association for Accessible Medicines (AAM), to discuss how U.S. purchasing dynamics and thin margins drive shortages, the evolving biosimilar landscape amid insurer vertical integration, the Inflation Reduction Act (IRA)’s ripple eff…

1
Patrick Kelly: Inside the Generic Supply Chain Squeeze 27:58

3M ago27:58

27:58

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Patrick Kelly, Chief Advocacy Officer at the Healthcare Distribution Alliance, to discuss why generic markets face razor-thin margins and concentration risk, what is driving recent drug shortages, how tariffs and reshoring could affect costs, potential ripple effects fro…

1
Lieven Annemans & Andreas Charalambous: Moving the Needle in EU Cancer Care 40:07

4M ago40:07

40:07

In this Vital Health Podcast, host Duane Schulthess speaks with two leading European voices on oncology and health economics: Andreas Charalambous: Chair of Nursing at Cyprus University and Executive Board Member at MASCC, former President of the European Cancer Organization, Director of the Research Center for Oncology and Palliative Care at eOnco…

1
Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks 36:59

4M ago36:59

36:59

Kirsten Axelsen is an economist specializing in Medicare reimbursement, payer negotiations, and innovative reimbursement contracts. She’s a fellow of the Aspen Institute and a visiting scholar with the American Enterprise Institute. She joins host Duane Schulthess to unpack bipartisan pressure on drug prices, the Part D redesign’s rapid shift of ca…

1
Best-of Edition: Pernille Weiss & Niklas Blomberg on EU Pharma Policy 52:58

4M ago52:58

52:58

In this "Best-of" edition of the Vital Health Podcast, Duane Schulthess revisits two listener favorites on the future of medicines in Europe. First, former MEP Pernille Weiss explains how the European Parliament reshaped the EU’s General Pharmaceutical Legislation (GPL) to better support innovation while respecting member state control over pricing…

1
Henry Skinner: Fixing the Antibiotics Market & Confronting AMR 29:37

5M ago29:37

29:37

In this Vital Health Podcast, host Duane Schulthess - joined by Joe Hammang, Vital Transformation's US Business Director - speaks with Henry Skinner (CEO, AMR Action Fund), about the escalating threat of antimicrobial resistance (AMR) and what it will take to rebuild a viable antibiotics pipeline. The conversation follows the full story - from beds…

1
Best-of Edition: Peter Kolchinsky & John LaMattina on the IRA 59:07

5M ago59:07

59:07

In this “Best of” edition, host Duane Schulthess revisits two landmark conversations on the long-term impact of the Inflation Reduction Act (IRA) on the biopharmaceutical industry. First, Peter Kolchinsky (Managing Partner, RA Capital Management; Steering Committee Member, No Patient Left Behind), explains why nine-year negotiation timelines for sm…

1
Barbara McAneny, Rafael Fonseca, and Steve Potts: Protecting Patients Amid the IRA 36:50

5M ago36:50

36:50

In this episode of the Vital Health Podcast, host Duane Schulthess convenes three leading voices from the 2025 BIO International Convention - prominent physicians, innovators, and advocates shaping the future of drug development in the wake of the Inflation Reduction Act (IRA). Throughout this conversation, they examine policy impacts, clinical ram…

1
Sam Rasty, Steve Potts, and Joe Hammang: Policies, Patients, and the Biotech Narrative 41:29

6M ago41:29

41:29

In this episode, Duane Schulthess is joined by Sam Rasty, Chief Business Officer at Sensorium Therapeutics, Steve Potts, Chair of the Drug Development Council at the International Cancer Advocacy Network, and Joe Hammang, neuroscientist and US Business Director at Vital Transformation, to discuss how U.S. health policy is reshaping neuroscience inn…

1
Ipsita Smolinski: Drug Pricing, R&D, & Global Policy 26:38

6M ago26:38

26:38

In this episode, host Duane Schulthess sits down with Ipsita Smolinski, Founder and Managing Director of Capitol Street and faculty at Georgetown University and Johns Hopkins Carey Business School. They unpack the Inflation Reduction Act’s drug-pricing mechanisms, assess economic projections against emerging industry data, and discuss how changing …

1
Strengthening Biotech Ecosystems: Steve Potts & Robert Coughlin 44:01

7M ago44:01

44:01

In this Vital Health Podcast episode, host Duane Schulthess sits down with Steve Potts, biopharma entrepreneur and chair of the Drug Development Council (ICAN), and Robert Coughlin, Managing Director of Life Sciences at Jones Lang LaSalle, to explore how recent policy changes are reshaping the future of drug development. They unpack the unintended …

1
Jocelyn Ulrich: PBMs, Policy Risk, and Biopharma’s Future 31:38

7M ago31:38

31:38

In this Vital Health Podcast, host Duane Schulthess speaks with Jocelyn Ulrich, Vice President of Policy and Research at PhRMA, to discuss the far-reaching implications of current U.S. drug pricing and reimbursement policies. With a unique journey from opera stages to Senate testimony, Ulrich brings both strategic acumen and firsthand experience in…

1
Jenni Nordborg: Life Sciences Governance & EU Regulatory Alignment 25:45

7M ago25:45

25:45

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with Jenni Nordborg, Director of International Affairs at The Swedish Association of the Pharmaceutical Industry (LIF), to explore how national and European policies intersect to shape life sciences innovation. They discuss Sweden’s holistic governance model, the strategic…

1
Donna Cryer: Advocacy, Drug Incentives & Research Crisis 49:05

8M ago49:05

49:05

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with patient advocate and Global Liver Institute founder Donna Cryer. They trace her journey from Harvard and the DOJ prosecutor’s office to becoming a liver transplant recipient and a leading voice in healthcare policy. Donna shares insights on orphan drug incentives, the…

1
VT’s Grumpies Talk IRA with Virginia Acha 58:34

8M ago58:34

58:34

In this special Grumpies episode, host Duane Schulthess, CEO of Vital Transformation, is joined by neuroscientist and US Business Director Joe Hammang, consulting economist Dr. Harry Bowen, and MSD Associate VP of Science and Regulatory Policy Virginia “Ginny” Acha. They examine the IRA and question its promise to lower drug prices for Medicare ben…

1
Steve Usdin: Tariffs, Price Controls, & Inflation Reduction Act (IRA) 56:35

8M ago56:35

56:35

In this episode, host Duane Schulthess sits down with Steve Usdin, Senior Washington Editor at BioCentury Publications since 1993 and one of the most cited experts on FDA regulation, Medicare policy and the political forces driving biopharma innovation, to explore the major forces reshaping U.S. life sciences: looming Section 232 tariff probes, the…

1
Expanding Oncology Treatments: PRIME-ROSE and the Future of Drug Repurposing 26:55

10M ago26:55

26:55

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two key voices driving the PRIME-ROSE initiative: Gro Live Fagereng, Project Manager of the EU-project PRIME-ROSE and Coordinator of Precision Cancer Medicine at Oslo University Hospital, and Henk van der Pol, Ph.D. Candidate at Leiden University Medical Center. They exp…

1
Breaking Barriers: The Prime Rose Project and Off-Label Drug Innovations 29:15

1y ago29:15

29:15

Join host Duane Schulthess on the Vital Health Podcast as he explores the groundbreaking Prime Rose Project, an initiative redefining the use of off-label drugs in oncology. Featuring insights from Dr. Hans Gelderblom, Chair of Medical Oncology at Leiden University Medical Center, and Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, a member of t…

1
Impact of the Inflation Reduction Act on Venture Capital in Life Sciences 36:11

1y ago36:11

36:11

In this Vital Health Podcast, John Stanford, Executive Director of Incubate, discusses the impact of the Inflation Reduction Act (IRA) on venture capital investments in life sciences. Stanford emphasizes that the IRA's price control mechanisms have led to significant shifts in funding, particularly away from small-molecule drug development, creatin…

1
Investing in Health: Pathways to a Well-being Economy and Smarter Healthcare Budgets 35:30

1y ago35:30

35:30

In this insightful episode of the Vital Health Podcast, we dive deep into the economic and societal benefits of investing in healthcare. Our esteemed guests, Professor Herwig Ostermann, Executive Director, Austrian National Public Health Institute, Professor Dennis A. Ostwald, CEO, WifOR Institute and Professor at Steinbeis School of International …

1
Addressing Europe's Health Challenges: Innovation, Prevention, and Policy 38:30

1y ago38:30

38:30

Join us at the Gastein Health Conference for an insightful conversation on Europe's healthcare challenges and innovations! Host Duane Schulthess sits down with experts like Josep Figueras, the Founder and Director of the European Observatory on Health Systems and Policy, Francesca Colombo, the Head of the OECD Health Division, and Annemiek Verkamma…

1
The Future of Biotech: Steve Potts on Innovation, Policy, and the Impact of the IRA 24:58

1y ago24:58

24:58

In this episode of the Vital Health podcast, host Duane Schulthess sits down with Steve Potts, a seasoned entrepreneur and CEO of SLAM BioTherapeutics. They dive deep into the challenges and opportunities in biotech, exploring how recent legislative changes, like the IRA, are reshaping the industry. Steve shares insights on the shift from small mol…

1
Revolutionizing Healthcare with Real-World Data 27:13

1+ y ago27:13

27:13

In the latest episode of the Vital Health podcast, we delve into the future of healthcare with Blythe Adamson from Flatiron Health. Learn how Flatiron is at the forefront of transforming drug discovery through real-world data—using insights from everyday clinical practices to drive innovation and improve patient outcomes.Blythe shares fascinating i…

1
Exploring the Intersection of Intellectual Property and Biotech Innovation 56:52

1+ y ago56:52

56:52

In the latest episode of the Vital Health podcast, we engage in a thought-provoking discussion with Hans Sauer, Deputy General Counsel for Intellectual Property at the Biotechnology Innovation Organization (BIO), and Gwen O'Loughlin, a seasoned health data researcher. Together, they unpack the complexities of intellectual property (IP) in the rapid…

1
Unlocking the Power of Genomic Data: NashBIO's Role in Healthcare Innovation 19:00

1+ y ago19:00

19:00

In this episode of the Vital Health podcast, we dive deep into the world of genomic data and its transformative impact on healthcare. Join host Duane Schulthess as he sits down with Judsen Schneider, CTO of Nashville Biosciences, and Curt Allen, VP of Sales, to explore the origins and growth of Nashville Biosciences. Discover how this pioneering co…

1
MEP Pernille Weiss – Rapporteur of the EU GPL 47:33

1+ y ago47:33

47:33

In this Vital Health Podcast, Duane Schulthess speaks to Pernille Weiss, a former Member of the European Parliament and the Rapporteur of the European Parliament’s revision of the EU's General Pharmaceutical Legislation (GPL). The GPL proposes many profound changes to the regulatory structures of the EU’s pharmaceutical sector, and MEP Weiss sat at…

1
Transforming Health Communications: Insights from Virginia Amann 26:51

1+ y ago26:51

26:51

Join us at the International 2024 BIO conference as host Duane Schulthess sits down with Virginia Amann, CEO of the Entente Network. Discover how Virginia has led her firm to become a global leader in strategic communications, crisis management, and behavior science. They discussed the firm's mission to secure positive outcomes for clients, the imp…

1
Joe Panetta – Policy Impacts on California Biopharma 27:30

1+ y ago27:30

27:30

With the continuing pressure placed upon the US biopharma sector from Washington DC, how is the California biopharma ecosystem, arguably the leading hub for innovative biotech worldwide, responding? In this Vital Health Podcast, we speak with Joseph Panetta to discuss this issue. Joe is the President & CEO of Biocom California, an organization repr…

1
Niklas Blomberg, Executive Director, EU Innovative Health Initiative 19:58

1+ y ago19:58

19:58

In this Vital Health Podcast, recorded live at the 2024 Bio International Conference, host Duane Schulthess sits down with Niklas Blomberg, the Executive Director of the EU Innovative Health Initiative (IHI). Together, they delve into the transformative journey from the Innovative Medicines Initiative to the broader, more inclusive Innovative Healt…

1
Congressman Michael Burgess – IRA and March-in Rights 28:55

1+ y ago28:55

28:55

Congressman Michael Burgess is the Chair of the House Rules Committee and one of only 20 M.D.s currently serving in Congress. Before his election to the House of Representatives in 2002 for the 26th District in Texas, Congressman Burgess was a practicing physician in obstetrics and gynecology. In this Vital Health podcast, Congressman Burgess outli…

1
Kim Hawkins - Project Co-Lead of IMI’s Trials@Home 32:51

1+ y ago32:51

32:51

Trials@Home is a €39 million, pan-European public private partnership of the EU’s Innovative Medicines Initiative, focused on defining the best practices to conduct decentralised clinical trials (DCTs). In this Vital Health Podcast, Duane Schulthess speaks with Kim Hawkins, Global Head of Clinical Project Operations at Sanofi, and the Co-Project Le…

1
Douglas Holtz-Eakin, “Indications are going to be deeply affected by the IRA” 54:59

1+ y ago54:59

54:59

Douglas Holtz-Eakin was formerly a professor of economics at Syracuse University and served as the director of the Congressional Budget Office from 2003 – 2005. He was the chief economic policy adviser to Senator John McCain's 2008 presidential campaign and is currently president of the American Action Forum, a highly respected think tank in Washin…

1
John LaMattina – Drug Price Controls and IP Attacks Get Real 32:43

2y ago32:43

32:43

John LaMattina was President of Pfizer Global Research and Development and ran an international team of over 13,000 scientists and professionals. He has authored several books, including the highly acclaimed Pharma and Profits – Balancing Innovation, Medicine, and Drug Prices. He is also a senior partner at PureTech Health and a contributor to Forb…

1
Kate Hudson & Joseph P. Allen – The Fact Free Attacks on IP 35:41

2y ago35:41

35:41

This podcast features Kate Hudson, the Associate Vice President and Counsel for Policy at the Association of American Universities, and Joseph P. Allen, the Executive Director of the Bayh-Dole Coalition. They discuss the unintended consequences that the Biden Administration’s Draft Interagency Guidance Framework for Considering the Exercise of Marc…

1
VT’s Grumpy Old Men – The Administration’s Threats to use March-In Rights 53:48

2y ago53:48

53:48

On December 8, 2023, The Biden Administration under the National Institute of Standards and Technology (“NIST”) released a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights in the Bayh-Dole Act. VT’s Grumpy Old Men are back to discuss what this means to R&D. Vital Transformation released our report, March-in right…

1
PRIME-ROSE: The EU’s DRUP Trial Champion 25:44

2y ago25:44

25:44

With a six million EUR funding grant from the European Commission, the PRIME-ROSE project will implement, across Europe, a series of prospective, non-randomized clinical trials known as DRUP trials. DRUP trials started in the Netherlands and have successfully increased inclusion rates to offer additional lines of treatment to patients. On this Vita…

1
Peter Kolchinsky - "IRA's 9 Years Is Too Short" 56:37

2y ago56:37

56:37

In this Vital Health Podcast, Duane Schulthess speaks with Peter Kolchinsky, Managing Partner at RA Capital Management. Peter has authored several critically acclaimed books, including The Great American Drug Deal and The Entrepreneur’s Guide to a Biotech Startup. Peter also serves as the Director of No Patient Left Behind, a non-profit organizatio…

1
Christian Schneider, CMO Biopharma Excellence 49:05

2y ago49:05

49:05

Christian Schneider is the Chief Medical Officer of Biopharma Excellence, and was formerly the Chief Scientific Officer at the UK’s MHRA. He was the Medical Head for Licensing at the Danish Medicines Agency, and a member of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. In this podcast, we discuss the co…

1
Bettina Ryll at the 2023 ESMO Conference 40:37

2y ago40:37

40:37

On this Vital Health Podcast, Duane Schulthess has a conversation with Bettina Ryll, the founder of the Melanoma Patient Network Europe. Bettina is regarded as one of the world’s leading Patient Advocates, who dedicated herself to advocacy after the death of her husband from cancer. While most patient representatives don’t have a medical background…

1
Dan Leonard, Executive Director, We Work For Health 36:18

2y ago36:18

36:18

Dan is the newly appointed Executive Director of We Work For Health, bringing more than two decades of experience in advocacy, policy, and public affairs to this role. He previously headed the Association for Accessible Medicines (AAM) and the National Pharmaceutical Council (NPC). In this podcast, we discuss the ten drugs selected for negotiation …

1
Cancer Drug Developer Dr. Steve Potts' Congressional Testimony on the IRA 41:06

2+ y ago41:06

41:06

In this Vital Health Podcast, we’re speaking with Steve Potts before his congressional testimony for the U.S. House Committee on Energy and Commerce. Steve presented evidence regarding the negative impacts of the Inflation Reduction Act on U.S. venture capital investors, the development of small molecules, and the needed therapies that will most li…

1
Amy Miller and the PhRMA Foundation Push the R&D Envelope 38:15

2+ y ago38:15

38:15

In this vital health podcast, we’re speaking with Amy M. Miller, the recently appointed President of the PhRMA Foundation. Amy has held nonprofit leadership roles for nearly 20 years in DC, including President and CEO of the Society for Women’s Health Research and Executive Vice President of the Personalized Medicine Coalition. The PhRMA Foundation…

1
VT’s Grumpy Old Men on Price Controls and IP Attacks 54:23

2+ y ago54:23

54:23

The U.S. Congress and Biden Administration’s attacks on IP and Drug Pricing continue unabated as the 2024 election approaches. In this Vital Health Podcast, VT’s Grumpy Old Men (Duane Schulthess, Joe Hammang, and Harry P. Bowen) are particularly grumpy about the current state of affairs and dig into their research findings on the Inflation Reductio…

1
Taking the Helm Mid Drug Pricing Maelstrom 32:14

2+ y ago32:14

32:14

In this Vital Health Podcast, Duane Schulthess speaks with Rachel King, the Interim CEO of the Biotechnology Innovation Organization (BIO), who is steering the organization through the increasingly choppy waters of the DC drug pricing debate. With mounting regulatory pressure from all angles towards the global biopharma sector, Washington DC’s BIO …

Podcasts Worth a Listen

Andreas Ryll Podcasts

Podcasts Worth a Listen

Quick Reference Guide